Though cardiac transplantation markedly improves quality of life and provides a cost effective alternative to medical therapy, the number of donor organs is restricted.'2 Overall success is also limited by the complications of chronic immunosuppression, opportunistic infection, and the development of allograft coronary artery disease requiring retransplantation in 40% of patients by six years. 34 In the absence of a realistic alternative, transplantation discards some poorly functioning but potentially recoverable hearts, particularly in dilated cardiomyopathy, viral myocarditis, or protozoal -infections. In contrast, modern blood pumps can offload the failed left ventricle and encourage an element of recovery. There is now the prospect of improved mechanical devices that, without the risks of immunosuppression or organ rejection, will relieve symptoms and prolong life in many heart failure patients. Existing devices for mechanical cardiac support used as a bridge to transplantation function for prolonged periods without blood damage or risk of infection.5-7 The new intraventricular axial flow pumps now under investigation provide better prospects for permanent mechanical support and will become the artificial hearts of the relatively near future. Such devices provide the opportunity to intervene early before multisystem failure develops and to combine coronary or valve surgery with ventricular support. There remains the option to explant the device should the myocardium recover.
Experience with devices used as a mechanical bridge to transplant The concept of a mechanical bridge to transplantation ( Electrical energy is converted into hydraulic work which ejects blood from the pump. The blood sac has a highly smooth surface which is designed not to require anticoagulation. The electrical power cable is brought out percutaneously from the right lower quadrant of the abdomen to connect to an extracorporeal control console and battery power system.Though successful as a bridge to transplantation, the noise of the device, together with the length of the inflow graft and a significant incidence of thromboembolism, limit its potential use as a permanent implant."I The Thermo Cardiosystems Heartmate vented electric LVAD (fig 2A and B) consists of a positive displacement, pusher plate pump activated by a low speed torque motor that can produce a stroke volume of 83 ml at rates varying from 50 to 120 beats per minute. 4 The electromechanical actuator fits beneath the pumping diaphragm and converts the rotary motion of the torque motor to the linear motion of the pump diaphragm ( fig 3) . After the motor switches on and makes one complete revolution pushing the diaphragm, blood ejects from the pump. The motor then turns off and the pump passively refills. There is a short inlet conduit which fits directly into the apex of the left ventricle and a longer outlet tube to the ascending aorta. Both the inlet and outlet conduits are fitted with 25 mm porcine valves (Medtronic Blood Systems). The flexing diaphragm is fabricated from biomer polyurethane and has an integrally textured fibrillar surface. All metal components have a sintered titanium/blood interface. This is a counter intuitive approach to thromboembolism whereby the textured surface promotes the formation of a fibre and cellular coagulum that evolves into a blood compatible biological lining. ' About 80% of the haemodynamic work of the heart is performed by the left ventricle. Right ventricular failure can usually be treated medically after implantation of an LVAD and may be avoided by earlier intervention. The use of a biventricular artificial heart is then unnecessary. It is now clear that moribund heart failure patients can improve to NYHA I and return to the community with an LVAD. Pilot programmes in the United States show that well-motivated LVAD patients can return to work or higher education while they wait for a transplant. In some instances use of the device has reduced inpatient costs from $5000 Percutaneous vent and electric lead per day in the intensive care unit to less than $50 per day with the patient at home.
The success of the outpatient LVAD programme provides a powerful argument for the use of the electric LVAD as an alternative to cardiac transplantation. In the United States in 1991 3797 patients were registered on the heart transplant waiting list with a median waiting period of 198 days: 2107 patients underwent heart transplantation and 778 patients died waiting.23 Data from the United Network for Organ Sharing have shown that a male with type 0 blood group, weighing more than 90 kg will wait a mean time of 595 days for a donor organ.23 Half of this patient group die before transplantation. Consequently, as many as 66 000 end stage cardiac patients per year may be candidates for mechanical circulatory support in the USA alone.24 Unlike the supply of donor hearts, the availability of LVADs is limited only by the industrial capacity for production.
Ultimately, long-term mechanical cardiac assistance may prove less expensive than cardiac transplantation or the intensive medical Figure 5 The Jarvik 7 pneumatic total artificial heart. treatment of patients in NYHA classes III and IV. Medically treated patients are admitted to hospital a mean of 10 I/min at a mean aortic pressure greater than 80 mm Hg. Blood entering the dilated left ventricle through the mitral valve is withdrawn via a Dacron graft to the descending thoracic aorta. The normal anatomical relations of flow into and out of the heart are retained but an additional second outlet is provided across the apex to the descending thoracic aorta. The pump unloads the natural left ventricle and allows the diseased heart to provide part of the cardiac output and pulsatility. In its apical position the device does not interfere with the papillary muscles or chordae tendineae and because there are no valves and only one moving part it has a potential life span of several decades. The principal issues of system reliability involve the durability of the blood-immersed bearings, flex fatigue of the electric wires, and the reliability of the electronic system including the batteries. Preliminary work in Oxford and The Texas Heart Institute suggests that the Jarvik 2000 can function free of thrombus formation and with insignificant heat generation or haemolysis. Patient mobility is expected to be entirely normal and those implanted with this system would require only anticoagulation with warfarin (international normalised ratio between 2-0 and 3 0). No immunosuppressive agents are needed and the risks of infection are small. Since an organ donor is not required, the system should be implanted before the onset of multisystem organ failure and might prevent further deterioration in left ventricular function. This will be the first implantable device suitable for use in children.
These and other developments over the past decade indicate that mechanical support can provide effective treatment for congestive heart failure. There is every likelihood that mechanical blood pumps will become as applicable to the treatment of heart failure as the pacemaker is to rhythm disturbances.
